Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Distribution Solutions Group, Inc. (DSG) and its officers or directors, following a significant drop in the company's stock price after its financial results announcement [1][3]. Financial Performance - On March 5, 2026, DSG reported its full year and fourth quarter 2025 financial results, with CEO Bryan King acknowledging the challenges faced in 2025, particularly those related to tariffs [3]. - The company's stock price fell by $7.81 per share, or 26.29%, closing at $21.90 per share on the same day [3]. Management Statements - Prior to the financial results announcement, CFO Ron Knutson had expressed confidence in managing the impact of tariffs, stating that DSG was "in a pretty good place around the tariff side" during a conference on November 18, 2025 [3].

Core Viewpoint - Pomerantz LLP is investigating claims on behalf of investors of Banco Santander, S.A. regarding potential securities fraud or unlawful business practices by the company and its officers or directors [1]. Group 1: Investigation and Claims - Pomerantz LLP is conducting an investigation into whether Santander and certain officers or directors have engaged in securities fraud or other unlawful business practices [1]. - Investors of Santander are encouraged to contact Pomerantz LLP for more information regarding the investigation [1]. Group 2: Market Impact - On February 27, 2026, a Reuters article reported the collapse of UK mortgage provider Market Financial Solutions Ltd, raising concerns about potential wider losses among banks, including Santander [3]. - Following the publication of the Reuters article, Santander's American Depositary Share (ADS) price fell by $0.98, or 7.57%, closing at $11.96 per ADS on February 28, 2026 [4].

NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Apollo Global Management, Inc. (“Apollo” or the “Company”) (NYSE: APO). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Apollo and certain ...

Core Viewpoint - Kaskela Law is investigating Reservoir Media, Inc. on behalf of long-term investors to determine potential violations of securities laws or breaches of fiduciary duties related to recent corporate actions [1]. Group 1 - The investigation is focused on whether Reservoir Media and/or its representatives acted inappropriately concerning their obligations to shareholders [1]. - Investors interested in the investigation can contact Kaskela Law for more information regarding their legal rights and options [2]. - Kaskela Law specializes in representing investors in cases of securities fraud, corporate governance, and merger & acquisition litigation [2].

Core Viewpoint - A class action lawsuit has been filed against Enphase Energy, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from April 22, 2025, to October 28, 2025, seeking damages for misleading statements regarding the company's business and financial prospects [1][7]. Group 1: Lawsuit Details - The class action was filed in the United States District Court for the Northern District of California, seeking to recover damages for all persons and entities that purchased Enphase securities during the specified Class Period [1]. - Investors have until April 20, 2026, to request appointment as Lead Plaintiff for the class [2]. Group 2: Company Background - Enphase Energy, founded in March 2006, focuses on solar generation, storage, and communication solutions, partnering with financing companies to offer third-party ownership arrangements for solar and battery products [4]. - The company reported "safe harbor revenue," defined as sales made to customers planning to install Enphase products over more than a year [4]. Group 3: Tax Credit Context - The Residential Clean Energy Credit allowed homeowners to deduct 30% of costs for clean energy property installed at their homes, which was favorable for solar products, including those from Enphase [5]. - The 25D Credit was set to terminate on December 31, 2025, seven years earlier than originally planned, impacting the financial outlook for Enphase [6]. Group 4: Allegations and Financial Impact - The Complaint alleges that Enphase made materially false and misleading statements about its ability to manage channel inventory and mitigate the effects of the 25D Credit termination, overstating its financial and operational prospects [7]. - Following the announcement of weak financial results and expectations for lower battery storage shipments, Enphase's stock price fell by $5.56 per share, or 15.15%, closing at $31.14 on October 29, 2025 [8][9].

Group 1 - A class action lawsuit has been filed against Ultragenyx Pharmaceutical Inc. for alleged securities fraud and unlawful business practices [2] - Investors who purchased Ultragenyx securities during the Class Period have until April 6, 2026, to request appointment as Lead Plaintiff [2] - The lawsuit is being handled by Pomerantz LLP, a firm recognized for its expertise in corporate and securities class litigation [6] Group 2 - On July 9, 2025, Ultragenyx announced progress in the Phase 3 Orbit study for UX143, leading to a stock price drop of $10.41 per share, or 25.11%, closing at $31.04 on July 10, 2025 [4] - On December 29, 2025, Ultragenyx reported that its Phase III Orbit and Cosmic Studies failed to meet primary endpoints, resulting in a stock price decline of $14.47 per share, or 42.32%, closing at $34.19 [5]

Core Viewpoint - A class action lawsuit has been filed against Nektar Therapeutics and certain officers for alleged violations of federal securities laws during the Class Period from February 26, 2025, to December 15, 2025, seeking damages for affected investors [1]. Company Overview - Nektar Therapeutics is a biopharmaceutical company focused on developing therapies that modulate the immune system for treating autoimmune disorders [4]. - The company's lead product candidate is rezpegaldesleukin (REZPEG or NKTR-358), aimed at treating conditions such as alopecia areata [4]. Clinical Trial Information - In March 2024, Nektar initiated the Phase 2b REZOLVE-AA trial to evaluate rezpegaldesleukin in 94 patients with severe-to-very severe alopecia areata [5]. - The trial's enrollment criteria included specific diagnostic and treatment history requirements to ensure patient eligibility [5]. - By February 2025, Nektar announced the completion of target enrollment for the REZOLVE-AA trial, asserting compliance with applicable protocols [6]. Allegations and Misconduct - The lawsuit alleges that throughout the Class Period, Nektar's executives made materially false and misleading statements regarding the company's operations and compliance, particularly concerning the REZOLVE-AA trial [7]. - Specific allegations include failure to disclose that enrollment in the trial did not adhere to protocol standards, which could negatively impact trial results and overall integrity [7]. Disclosure of Trial Results - On December 16, 2025, Nektar released topline results from the REZOLVE-AA trial, revealing that the trial did not achieve statistical significance due to the inclusion of ineligible patients [8]. - Following this announcement, Nektar's stock price dropped by $4.14 per share, or 7.77%, closing at $49.16 per share [9].

Core Viewpoint - A class action lawsuit has been filed against Bath & Body Works, Inc. concerning allegations of securities fraud and unlawful business practices [2]. Financial Performance - On August 28, 2025, Bath & Body Works reported earnings per diluted share of $0.30, a decline of 55.8% year over year, and net income of $64 million, down 57.9% year over year [4]. - The company cut its full year guidance for earnings per diluted share by $0.03, adjusting it to a range of $3.28 to $3.53 [4]. - Following this announcement, the stock price fell by $2.18 per share, or 6.9%, closing at $29.36 [5]. - On November 20, 2025, the company reported a 1% year over year decline in revenue, missing its guidance of 1-3% growth [6]. - Net income for the third quarter also declined by 26% to $77 million, and the full year guidance for net sales was slashed from a positive 1.5%-2.7% to negative "high single digits" [6]. - Expected earnings per diluted share were cut from a range of $3.28 to $3.53 to "at least $2.83" [6]. - The stock price fell by $5.22 per share, or 24.8%, closing at $15.82 [6]. Legal Context - Investors who purchased Bath & Body Works securities during the Class Period have until March 16, 2026, to request to be appointed as Lead Plaintiff [2].

Core Viewpoint - A class action lawsuit has been filed against Lakeland Industries, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from December 1, 2023, to December 9, 2025, seeking damages for affected investors [1]. Company Overview - Lakeland Industries, Inc. manufactures and sells industrial protective clothing and accessories globally, employing a "small, strategic, and quick" mergers and acquisitions strategy to drive growth in revenue and profitability [4]. Recent Acquisitions - In November 2023, Lakeland announced the acquisition of Pacific Helmets, a leading designer and manufacturer of helmets for firefighting and rescue markets, claiming it enhanced their product portfolio [5]. - In February 2024, Lakeland acquired Jolly Scarpe S.p.A. and Jolly Scarpe Romania S.R.L., known for professional footwear for firefighting and military markets, which was touted as a significant milestone in their expansion efforts [6]. Financial Performance and Guidance - Throughout the Class Period, Lakeland's management consistently represented that the company would benefit significantly from its acquisitions and was well-positioned to handle tariff-related challenges, maintaining confidence in their financial guidance [7]. - In July 2024, management projected adjusted EBITDA for FY 2025 to be between $18 million and $21.5 million, reaffirming expectations of at least $18 million [8]. - In April 2025, management forecasted FY 2026 revenue of $210 to $220 million and adjusted EBITDA of $24 to $29 million, despite tariff uncertainties [9]. Allegations of Misleading Statements - The lawsuit alleges that management made materially false and misleading statements regarding Lakeland's business operations and prospects, including issues with the Pacific Helmets and Jolly businesses, which were not disclosed [10][11]. - Specific issues cited include shipping delays, production problems, and a slower rollout of new products, which negatively impacted financial results and guidance [10][11]. Stock Price Reactions - Following the release of disappointing financial results, Lakeland's stock price experienced significant declines, including a drop of 7.82% on September 5, 2024, after missing revenue estimates [12]. - Subsequent earnings reports in April 2025 and June 2025 also led to stock price declines of 14.33% and 22.16%, respectively, due to continued production issues and tariff-related delays [13][14]. - On December 10, 2025, after announcing further disappointing results and withdrawing financial guidance, the stock fell by 38.97% [16][17].

Core Viewpoint - The Boston Scientific Corporation is facing a class action lawsuit due to alleged violations of the Securities Exchange Act of 1934, with claims that the company misled investors regarding its revenue outlook and market share growth during a specific period [1][3]. Company Overview - Boston Scientific develops, manufactures, and markets medical devices for various interventional medical specialties globally [2]. Allegations of the Lawsuit - The lawsuit claims that Boston Scientific and its executives made false or misleading statements about the company's revenue projections and growth potential, particularly in the Electrophysiology market, where new competition has impacted its market share [3]. - Specific allegations include the failure to disclose risks related to seasonality and macroeconomic fluctuations, which contributed to an overly optimistic portrayal of the company's growth trajectory [3]. Financial Performance - On February 4, 2026, Boston Scientific reported its fourth quarter and full year 2025 financial results, revealing a GAAP net income of $672 million or $0.45 per share for Q4 2025, an increase from $566 million or $0.38 per share a year prior [4]. - For the full year 2025, the company reported a GAAP net income of $2.898 billion or $1.94 per share, compared to $1.853 billion or $1.25 per share the previous year, with adjusted EPS rising to $3.06 from $2.51 [4]. - The reported EPS for Q4 was below the company's guidance range of $0.48 to $0.52, leading to a stock price drop of over 17% following the announcement [4]. Legal Process - Investors who purchased Boston Scientific common stock during the class period have until May 4, 2026, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm to litigate the case [5]. Law Firm Background - Robbins Geller Rudman & Dowd LLP is a leading law firm in securities fraud and shareholder rights litigation, having recovered over $916 million for investors in 2025 alone [6]. - The firm has a strong track record, recovering $8.4 billion for investors over the past five years, making it one of the largest plaintiffs' firms globally [6].